The market for cardiac catheterization is significantly influenced by the growing demand for diagnostic procedures related to cardiovascular diseases. As heart-related conditions continue to rise globally, healthcare providers increasingly rely on cardiac catheterization for accurate and detailed diagnostic information.
Technology improvements in heart catheterization processes keep helping the market grow. Improvements like better pictures, 3D maps and real time watching make heart catheter work more accurate. Both doctors and patients are interested in it now.
The world's older people is a big part of the market, because heart diseases happen more often as you get older. Older people often need heart tests more, making the market grow as age groups get older.
Many people get sick from lifestyle issues like being heavy or having diabetes. This leads to a need for special heart tests called cardiac catheterization procedures. These things make heart problems more likely, so we need tests and treatments like checking the heart with a tube.
Learning more and teaching about heart health plus early signs of problems are important for markets. They help to catch issues before they get bad. People want more cardiac catheterizations because they're learning about their heart health from public education campaigns and healthcare programs. This helps them take better care of their hearts over time.
Payment plans for heart tests can affect how much they cost. When doctors are paid well, they provide these treatments. This makes them easier for more patients to get and helps the market grow bigger.
The money put into hospitals and medical centers also affects the market for cardiac catheterization. Hospitals with good gear and first-rate cath labs bring in more patients. More money spent on healthcare stuff helps the whole market grow too.
The rules, like getting approval and following standards, affect the market for heart catheterization. Strict rules make sure that medical procedures are safe and work well. They also build trust in doctors, nurses and patients alike while helping the market grow bigger.
Competition between medical device companies and healthcare places pushes for new ideas and effectiveness in heart catheterization machines. Competition in the market pushes for better and low-cost solutions. This helps service providers as well as patients.
The global economic landscape plays a role in the cardiac catheterization market, as economic stability and growth influence healthcare spending. Economic downturns can impact the adoption of expensive medical procedures, while periods of economic prosperity may lead to increased investment in healthcare infrastructure and services.
Report Attribute/Metric | Details |
---|---|
Market Size Value In 2023 | USD 0.3731billion Billion |
Growth Rate | 7.4% (2023-2032) |
Cardiac Catheterization Market Size was valued at USD 0.35 billion in 2022. The Cardiac Catheterization market industry is projected to grow from USD 0.3731 Billion in 2023 to USD 26.4 billion by 2032, exhibitinga compound annual growth rate (CAGR) of 7.4% during the forecast period (2023 - 2032).
An increased number of technologically advanced devices and increased awareness of healthcare and reimbursement policies are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
It was in February 2023 that Abbott made public the approvals of TactiFlex and FlexAbility catheters, electrophysiology products. The world’s first flexible tip, contact force sensing ablation catheter to have received CE Mark and be released into the European market for treating such patients with abnormal heart rhythms as atrial fibrillation (AFib) is TactiFlex. Also, FlexAbility ablation catheter received approval from U.S. FDA to treat patients having complex heart diseases.
In May 2022, Medtronic announced that its IN.PACT 018 PTA Balloon Catheter – a DCB meant for the interventional treatment of PAD in SFA & popliteal arteries has been given FDA approval.
Moreover, BIOTRONIK, an international medical technology company based in Germany on September 2021 extended its Fortress Reinforced Introducer Sheath line with two new additional sizes consisting of seven and eight French compatible sizes.
U.S.-based pharmaceutical firm Aytu BioPharma announced last November that it obtained a U.S. patent from the U.S. Patent and Trademark Office covering innovations with respect to Healight ultraviolet-A light-based pulmonary catheter.
The Flume Catheter Company Ltd., headquartered in UK, revealed on November this year that it had received permission from the US FDA to market FLUME catheter into US market.
Such as Medtronic launched Prevail—a new-generation drug-coated balloon (DCB) catheter—in June 2021 in the European market for CAD treatment. This DCB is used during PCI surgery as a way to unblock or widen narrowed coronary arteries in individuals suffering from CAD.
Similarly, in January 2021, Medical Manufacturing Technologies, a portfolio firm of Arcline investment management that provides medical device manufacturing solutions, integrated Biomerics R&D Engineering into its automation technologies and catheter manufacturing, expected to push growth in the industry.
A growing number of older adults are driving the market growth
One of the significant concerns in the world's emerging nations is the growing elderly population. The incidence of chronic illnesses in older people, such as aortic disease, venous thromboembolism, peripheral arterial disease, etc., is also expected to increase throughout the forecast period, driving the expansion of the catheter market.
Geriatric populations are growing unprecedentedly in the Asia Pacific, where most of them exist. One of the biggest worries in the world's emerging nations is the growing elderly population. The incidence of chronic illnesses in older people, such as aortic disease, venous thromboembolism, peripheral arterial disease, etc., is also expected to increase throughout the forecast period, driving the expansion of the catheter market CAGR.
Additionally, Minimally invasive techniques are mostly painless and need reduced hospital stays compared to traditional open heart surgery, which minimizes recovery periods as well as the cost of healthcare. These procedures are an essential component of the cardiovascular care pathway since they entail the utilization of catheters and guidewires to maneuver through the blood arteries and carry out interventions. The presence of qualified healthcare practitioners, rising consumer awareness about the advantages of minimally invasive treatments, and developments in related technology are anticipated to fuel industry growth.
Moreover, the Lubricity of catheters and guidewires is being improved by applying specific coatings, such as hydrophilic coatings. The precision of these devices is thus enhanced, and navigational friction is also reduced. Robotics and 3D imaging technology are making it possible to implant catheters and guidewires more precisely, lowering the likelihood of problems and improving patient outcomes. These developments are anticipated to propel the Cardiac Catheterization market revenue growth during the forecast period.
Based on type, the Cardiac Catheterization market segmentation includes fractional flow reserve, optical coherence tomography, intravascular ultrasound, and coronary angiogram. The coronary angiogram dominated the market, a widely used diagnostic tool to visualize the blood flow in the coronary arteries.Moreover, it is a relatively simple and safe procedure with a low risk of complications and is widely available. It can be performed quickly, making it a cost-effective option for diagnosing coronary artery disease.
The Cardiac Catheterization market segmentation, based on procedures, includes catheter ablation, coronary angioplasty, bipolar pacing, balloon septostomy, right heart catheterization, left heart catheterization, and others. Catheter ablation dominated the market; catheter ablations are used in catheter ablation, angioplasty, PCI, and other interventional procedures. Catheter Ablation is used to evaluate heart muscle function, estimate the need for further treatment, and evaluate the presence of valve disease & coronary artery disease.
Based on application, the Cardiac Catheterization market segmentation includes heart attack, cardiac arrhythmia, coronary vasospasm, abnormal stress test, and others. Heart attack dominates the market;the prevalence is due to the high incidence of heart attacks ly, which is expected to drive the growth of the cardiac catheterization market.
Based on end-user, the Cardiac Catheterization market segmentation includes hospitals, clinics, and others. The hospitals dominated the market; due to the high incidence of cardiovascular diseases ly, the rising number of hospitals across the globe is also anticipated to support the segment growth over the forecast period.
Figure 1 Cardiac Catheterization Market, by End-user, 2022 &2032 (USD billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American cardiac catheterization market will dominate due to the increased adoption of cardiac catheters and guidewire technology in primary care settings, improved accessibility, and high healthcare spending in countries with efficient reimbursement policies will boost the market growth in this Region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 CARDIAC CATHETERIZATION MARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Cardiac Catheterization market accounts for the second-largest market share due to technological innovations and the growing incidence of chronic conditions is anticipated to propel the Region's growth. Further, the German Cardiac Catheterization market held the largest market share, and the UK Cardiac Catheterization market was the fastest-growing market in the European Region
The Asia-Pacific Cardiac Catheterization Market is expected to grow at the fastest CAGR from 2023 to 2032. This is because the rising prevalence of cardiac diseases has created a demand for cardiac catheters & guidewires equipment in this Region. Moreover, China’s Cardiac Catheterization market held the largest market share, and the Indian Cardiac Catheterization market was the fastest-growing market in the Asia-Pacific region.
Cardiac Catheterization Key Market Players& Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Cardiac Catheterization market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The cardiac catheterization industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Cardiac Catheterization industry to benefit clients and increase the market sector. In recent years, the Cardiac Catheterization industry has offered some of the most significant advantages to medicine. Major players in the Cardiac Catheterization market, including Boston Scientific Corporation (US), Coloplast (Denmark), Dispocard GmbH (Germany), Becton, Dickinson and Company (US), St. Jude Medical (US), Abbott (US), Johnson & Johnson Private Limited (US), Teleflex Incorporated (US)., Smiths Medical (US), Edwards Life Sciences Corporation (US), Medtronic Inc (US), Rochester Medical Corporation (US), Maquet Medical India Private Limited (India), Terumo Medical Corporation (Japan), and others, are attempting to increase market demand by investing in research and development operations.
Koninklijke Philips N.V., commonly shortened to Philips, is a Dutch multinational conglomerate corporation founded in Eindhoven in 1891. Since 1997, it has been mostly headquartered in Amsterdam, though the Benelux headquarters is still in Eindhoven. Royal Philips, a leading health technology company, introduced the first solid core pressure wire in the world for coronary artery interventional procedures, named OmniWire. The new ground-breaking product will enable physicians to easily maneuver the wire in the patient's circulatory system for measuring blood pressure and vessels, along with guiding the delivery of stents and catheters.
Johnson & Johnson is the world's largest and most broadly based healthcare company. We've been producing life-changing breakthroughs every day for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Those working in medical devices are 3-D printing artificial joints personalized for each patient, while pharmaceutical researchers use AI to discover lifesaving drugs. Imagine what the rest of our team of 134,000 people at 260 companies in more than 60 countries is accomplishing.Johnson & Johnson Medical Devices has announced that Biosense Webster’s QDot Micro radiofrequency ablation catheter received European CE mark approval.
Key Companies in the cardiac catheterization market include
Cardiac Catheterization Industry Developments
August 2020: Royal Philips, a leading health technology company, introduced the world's first solid core pressure wire for coronary artery interventional procedures, named OmniWire. The new ground-breaking product will likely enable physicians to easily maneuver the wire in the patient's circulatory system for measuring blood pressure and vessels, along with guiding the delivery of stents and catheters.
August 2020: Johnson & Johnson Medical Devices has announced that Biosense Webster’s QDot Micro radiofrequency ablation catheter received European CE mark approval.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)